Jacobs Levy Equity Management
NERV icon

Jacobs Levy Equity Management’s Minerva Neurosciences NERV Stock Holding History

Jacobs Levy Equity Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-60,893
Closed -$848K – 1044
2021
Q3 		$848K Sell
60,893
-27,239
-31% -$410K 0.01% 778
2021
Q2 		$1.64M Sell
88,132
-6,512
-7% -$140K 0.01% 639
2021
Q1 		$2.21M Buy
94,644
+20,965
+28% +$524K 0.02% 578
2020
Q4 		$1.38M Buy
73,679
+21,291
+41% +$536K 0.01% 651
2020
Q3 		$1.33M Buy
52,388
+20,111
+62% +$544K 0.01% 600
2020
Q2 		$932K Sell
32,277
-2,446
-7% -$143K 0.01% 681
2020
Q1 		$1.67M Sell
34,723
-12,057
-26% -$728K 0.02% 519
2019
Q4 		$2.66M Buy
46,780
+41,957
+870% +$1.85M 0.03% 494
2019
Q3 		$299K Sell
4,823
-18,216
-79% -$1.03M ﹤0.01% 775
2019
Q2 		$1.04M Buy
23,039
+6,493
+39% +$325K 0.01% 638
2019
Q1 		$1.04M Buy
16,546
+5,987
+57% +$360K 0.02% 652
2018
Q4 		$569K Sell
10,559
-750
-7% -$54.9K 0.01% 713
2018
Q3 		$1.14M Buy
11,309
+4,963
+78% +$373K 0.02% 628
2018
Q2 		$419K Buy
6,346
+184
+3% +$11.2K 0.01% 835
2018
Q1 		$308K Buy
6,162
+3,324
+117% +$160K 0.01% 865
2017
Q4 		$137K Buy
+2,838
New +$141K ﹤0.01% 939
2017
Q3 		– Sell
-3,563
Closed -$252K – 1003
2017
Q2 		$252K Hold
3,563
– – 0.01% 797
2017
Q1 		$231K Hold
3,563
– – ﹤0.01% 769
2016
Q4 		$335K Sell
3,563
-957
-21% -$97.7K 0.01% 748
2016
Q3 		$510K Sell
4,520
-150
-3% -$14.6K 0.01% 714
2016
Q2 		$381K Buy
+4,670
New +$297K 0.01% 828
2016
Q1 		– Sell
-1,990
Closed -$97K – 1160
2015
Q4 		$97K Buy
+1,990
New +$83.1K ﹤0.01% 741
2015
Q3 		– Sell
-3,925
Closed -$182K – 850
2015
Q2 		$182K Buy
+3,925
New +$167K ﹤0.01% 734

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SEI Investments
SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

Jacobs Levy Equity Management's NERV Position: Q4 2021 in Review

Jacobs Levy Equity Management sold out of Minerva Neurosciences (NERV) in Q4 2021, closing a stake of 60,893 shares — an estimated $848K sold.

Jacobs Levy Equity Management first reported a position in NERV in Q2 2015 and held it in 23 quarters. The position peaked at $2.66M in Q4 2019. 35 funds tracked by Wall St. Rank hold NERV as of Q4 2021.

  • Jacobs Levy Equity Management reported no remaining Minerva Neurosciences position as of Q4 2021 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 60,893 Minerva Neurosciences shares in Q4 2021, an estimated $848K.
  • Jacobs Levy Equity Management first reported a position in Minerva Neurosciences in Q2 2015 and held it in 23 quarters.
  • Jacobs Levy Equity Management's Minerva Neurosciences position peaked at $2.66M in Q4 2019.
  • 35 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q4 2021.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2021, filed 14 Feb 2022.